Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Telik discovers potent molecules inhibiting cancer
Telik has identified a class of selective small molecule inhibitors of aurora kinase A and B and VEGFR2. Treatment of human colorectal cancer cells with two of these
Telik has identified a class of selective small molecule inhibitors of aurora kinase A and B and VEGFR2. Treatment of human colorectal cancer cells with two of these
In a double-blind, placebo-controlled, four-week study with dose escalations in 414 adults aged 18 to 55 years, treatment with Vyvanse showed reduction in ADHD-RS-IV scores ranging from 16.2
CB7630 was administered once-daily to chemotherapy-naive patients with castration refractory prostate cancer (CRPC), who had progressive disease despite treatment with LHRH analogues and multiple other hormonal therapies. Of
The study showed that all 12 treated patients demonstrated a significant immune response after vaccination with Oncophage. Patients with minimal residual disease at time of first vaccination were
The company reported revenues of $0.5 million for the third quarter of 2007, compared to revenues of $0.4 million for the same period last year. Revenues for the
Revenue from research funding in the Q3 of 2007 decreased to $30,000 from $33,000 in 2006. Panacos research and development expenses in the Q3 of 2007 decreased to
The Melville, New York-based company reported a net income from continuing operations of $35.9 million for the three months ended September 30, 2007, compared with net income from
Net loss per share was $0.53 for the Q3 of 2007, compared with a net loss per share of $0.63 for the Q3 of 2006. Revenue was $5.7
In his order US District Judge Charles Shaw concluded “that the constructions of the disputed terms and phrases proposed by plaintiff are correct.” The lawsuit alleges that Open
Arius Trop-2 targeting antibody has demonstrated a significant anti-tumor effect in animal models of human pancreatic cancer, inhibiting tumor growth by up to 100%. Subsequent testing showed efficacy